Filtered By:
Management: National Institutes of Health (NIH)
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 769 results found since Jan 2013.
The Scientist Behind Some of the World ’s Best Coronavirus Images
From her laboratory in the far western reaches of Montana, Elizabeth Fischer is trying to help people see what they’re up against in COVID-19.
Over the past three decades, Fischer, 58, and her team at the Rocky Mountain Laboratories, part of the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases, have captured and created some of the more dramatic images of the world’s most dangerous pathogens.
“I like to get images out there to try to convey that this is an entity, to try to demystify it, so this is something more tangible for people,” says Fischer, on...
Source: TIME: Science - May 20, 2020 Category: Science Authors: Markian Hawryluk / Kaiser Health News Tags: Uncategorized COVID-19 Source Type: news
Association Between Mouth Breathing and Asthma: a Systematic Review and Meta-analysis
AbstractPurpose of ReviewThis systematic review and meta-analysis evaluated the association between asthma and mouth breathing. We performed a systematic search in the PubMed, SCOPUS, Lilacs, Web of Science, Google Scholar and OpenThesis databases.Recent FindingsAsthma is defined as a heterogeneous disease characterized by variable symptoms of wheezing, shortness of breath, chest oppression and/or cough, and limitation of expiratory airflow. Although several studies have examined the association between asthma and mouth breathing, there are no systematic reviews or meta-analyses that synthesize the available bodies of evid...
Source: Current Allergy and Asthma Reports - May 18, 2020 Category: Allergy & Immunology Source Type: research
Moderna ’s COVID-19 Vaccine Shows Promise, Generating Positive Immune Responses in an Early Study
Earlier today, the biotech company Moderna reported positive results from a phase 1 study of its experimental COVID-19 vaccine, which was was among the first to begin testing in healthy human volunteers in mid-March.
The study, led by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health, involves 45 healthy people who received one of three different doses of the vaccine. According to Moderna, there are encouraging early signs that the shot generates antibodies against the COVID-19 virus, SARS-CoV-2, in levels that were similar to or higher than those seen in the plasma of p...
Source: TIME: Health - May 18, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19
(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from coronavirus disease 2019 (COVID-19). The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the trial, which is being conducted by the NIAID-funded AIDS Clinical Trials Group (ACTG). Teva Pharmaceuticals is donating medications for the study.
Source: EurekAlert! - Infectious and Emerging Diseases - May 14, 2020 Category: Infectious Diseases Source Type: news
Clinical Trials in Public Health Emergencies: The Ebola and COVID Experiences
Source: National Institute of Allergy and Infectious Diseases [National Institutes of Health] (NIAID). Published: 5/13/2020.
This 58-minute presentation discusses issues related to designing and conducting treatment trials in outbreaks of Ebola and COVID-19 based on the speaker's experience with three studies: Prevail II (the West African Ebola virus disease study of ZMapp); PALM (the Democratic Republic of the Congo Ebola virus disease study of ZMapp, mAb114, REGN-EB3 and remdesivir); and ACTT-1 (the multinational, platform COVID-19 study of remdesivir vs. placebo). She discusses how a pandemic adds an overloaded medical...
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - May 13, 2020 Category: International Medicine & Public Health Source Type: news
The FDA has authorised remdesivir for use in COVID-19 patients: but there ' s no good evidence it reduces mortality, CEBM
Two weeks ago, the National Institutes of Health (NIH) announced in a press release that their clinical trial on the experimental antiviral drug remdesivir, run by the National Institute of Allergy and Infectious Diseases (NIAID), shows that it “accelerates recovery from advanced COVID-19”.
Source: Current Awareness Service for Health (CASH) - May 12, 2020 Category: Consumer Health News Source Type: news
Remdesivir Shows Promising Results as a Coronavirus Treatment, According to Drug Manufacturer Gilead
Gilead, a California-based biopharmaceutical company, released two encouraging reports about remdesivir, an experimental drug that is being tested as a COVID-19 treatment.
In one statement, the company said that a large study of remdesivir “met its primary endpoint”: meaning, in this case, that the researchers have concluded that hospitalized patients taking the drug appear to improve faster than patients given a placebo. The study is run by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health and involves severe patients at multiple centers across th...
Source: TIME: Health - April 29, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
North Carolina pharma RedHill to have second drug tested for potential Covid-19 treatment
With fresh data from existing trials treating Covid-19 patients in Italy and Israel, a Triangle drugmaker has announced a deal with the federal government to explore another drug as a treatment for U.S. patients.
Raleigh-based RedHill (NASDAQ: RDHL) has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) — part of the National Institutes of Health (NIH) — to use its drug for non-clinical tests to treat Covid-19.
The drug, RHB-107, is believed…
Source: bizjournals.com Health Care:Biotechnology headlines - April 22, 2020 Category: Biotechnology Authors: Seth Thomas Gulledge Source Type: news
NIAID Strategic Plan for COVID-19 Research FY2020 – FY2024
Source: National Institute of Allergy and Infectious Diseases [National Institutes of Health] (NIAID). Published: 4/22/2020.
This 12-page document details the National Institute of Allergy and Infectious Diseases (NIAID)'s plan for accelerating research to diagnose, prevent, and treat COVID-19. It builds on current trans-NIAID efforts to better understand SARS-CoV-2 pathogenesis, transmission, and mechanisms of protective immunity by expanding resources and activities that support rapid development of biomedical tools to more effectively combat the COVID-19 disease and pandemic.
(PDF)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - April 22, 2020 Category: International Medicine & Public Health Source Type: news
Rapid COVID-19 Vaccine Development: An Example of the Prototype Pathogen Approach for Pandemic Preparedness
Source: National Institute of Allergy and Infectious Diseases [National Institutes of Health] (NIAID). Published: 4/22/2020.
In this one-hour presentation, the speaker discusses the prototype pathogen approach for pandemic preparedness that has been applied to the Middle East respiratory syndrome coronavirus (MERS CoV) over the last seven years, and explains the prototype pathogen approach in the context of developing a rapid COVID-19 vaccine.
(Video or Multimedia)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - April 22, 2020 Category: International Medicine & Public Health Source Type: news
Managing Asthma during COVID-19: An Example for Other Chronic Conditions in Children and Adolescents
E.M Abrams is a collaborator with the Institute for Health Metrics and Evaluation, is on the National Advisory Board for Food Allergy Canada, has received moderator fees from Novartis, and is on the National Food Allergy Action Plan Action Steering Team for Food Allergy Canada. S.J. Szefler has consulted for Astra Zeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Propeller Health, Regeneron and Sanofi and has received research support from the National Institutes of Health, the National Heart, Lung and Blood Institute and the Colorado Department of Public Health and Environment Cancer, Cardiovascular and Pulmonary Disease Program.
Source: The Journal of Pediatrics - April 20, 2020 Category: Pediatrics Authors: Elissa M. Abrams, Stanley J. Szefler Tags: Commentary Source Type: research
Disposable N95 Masks Can Be Decontaminated, Researchers Confirm
Several methods are effective at killing the new coronavirus on N95 masks — primary protective gear for health care workers — for two or three rounds of use.
Source: NYT Health - April 16, 2020 Category: Consumer Health News Authors: James Gorman Tags: Masks Shortages Research Coronavirus (2019-nCoV) Ultraviolet Light National Institutes of Health Hydrogen Peroxide National Institute of Allergy and Infectious Diseases Kumar, Anand Munster, Vincent your-feed-healthcare Source Type: news
Biomedical Research Response to COVID-19: A View from NIAID (National Institute of Allergy and Infectious Diseases)
Source: National Institutes of Health (NIH). Published: 4/15/2020.
This hour-long presentation details how the National Institute of Allergy and Infectious Diseases (NIAID) has tapped existing coronavirus expertise and other assets during the COVID-19 pandemic to stand up research programs spanning basic virology and immunology through to countermeasure development (diagnostics, therapeutics, and vaccines). As the outbreak has expanded, so too has the NIAID research program and the scope of the problems it seeks to solve.
(Video or Multimedia)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - April 15, 2020 Category: International Medicine & Public Health Source Type: news
Birmingham work will support new clinical trial for COVID-19 treatment
BioCryst Pharmaceuticals has started open enrollment into a randomized, double-blind, placebo-controlled clinical trial for the effects of galidesivir in patients with COVID-19. The trial is being funded by the National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health.
BioCryst Pharmaceuticals (Nasdaq: BCRX), which was founded in Birmingham, said it will be conducting support work for this clinical trial in Birmingham. Although the company is based in North…
Source: bizjournals.com Health Care:Biotechnology headlines - April 14, 2020 Category: Biotechnology Authors: Tyler Patchen Source Type: news
Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19.
It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
